Get the Daily Brief
Latest Biotech News
Regeneron shelves 2seventy‑acquired CAR‑T – strategic pipeline pruning
Regeneron announced it will discontinue development of bbT369, a CAR‑T candidate acquired from 2seventy bio, halting plans to advance the asset into a planned phase II study. The company described...
LNP shapes mapped: structural study ties form to delivery efficiency
A multi‑institutional team from the University of Pennsylvania, Brookhaven National Laboratory and industry partners published a biophysical characterization of four lipid nanoparticle (LNP)...
Teamwork raced to make Baby KJ’s CRISPR therapy: months‑long feat
A coordinated collaboration between clinicians, academic labs and industry CDMOs produced a bespoke CRISPR‑based therapy for an infant with a lethal urea cycle disorder in a matter of months....
Nanopore cfDNA assay detects tissue‑of‑origin and pathogens in critical‑care plasma
Researchers demonstrated that nanopore sequencing of plasma cell‑free DNA can simultaneously capture tissue‑of‑origin signals and identify pathogenic sequences in critically ill patients. The...
Deep learning speeds antibiotic discovery — new computational scaffolds emerge
A Nature Biotechnology–reported effort showed deep‑learning models can accelerate identification of novel antibacterial scaffolds by mining chemical and biological data to prioritize candidates...
Biogen bets on C5aR1: $70M upfront for Vanqua’s preclinical immunology asset
Biogen announced an exclusive worldwide license for Vanqua Bio’s preclinical C5aR1 antagonist, paying $70 million up front and up to $990 million in milestone payments. The company will lead all...
Lilly rescues Adverum: buys cash‑strapped gene‑therapy developer for its phase‑3 asset
Eli Lilly agreed to acquire Adverum in a deal that secures the AAV-based gene therapy ixo‑vec, currently in a Phase 3 study for wet age‑related macular degeneration (wAMD). The purchase price is...
Inhibrx posts registrational win: ozekibart hits primary endpoint in chondrosarcoma
Inhibrx reported top‑line results from a registrational Phase II, showing ozekibart (INBRX‑109) achieved a statistically significant improvement in median progression‑free survival for advanced or...
Tango’s PRMT5 data clear way to pivotal pancreatic study — company to advance vopimetostat
Tango Therapeutics unveiled Phase I/II data for vopimetostat (TNG‑462), an MTA‑cooperative PRMT5 inhibitor, reporting response rates and progression‑free survival in MTAP‑deleted pancreatic ductal...
Gepotidacin’s approval for UTIs: fluoroquinolone‑alternative gets greenlight, gonorrhea review continues
Gepotidacin, an oral bacterial type II topoisomerase inhibitor, received FDA approval in March 2025 for uncomplicated urinary tract infections under the brand Blujepa and remains under FDA review...
LNP structure and rapid CRISPR manufacturing: delivery tech meets bespoke gene cures
Two studies surfaced this week that target bottlenecks in nucleic acid therapeutics: a Nature Biotechnology report mapped diverse lipid nanoparticle (LNP) shapes and linked structural differences...
Remix shows first tumor shrinkage with small‑molecule mRNA degrader in rare cancer
Remix Therapeutics disclosed the initial signs of tumor shrinkage in a patient with a rare salivary gland cancer treated with its small‑molecule mRNA degrader platform. The company reported early...
Merus widens oncology reach: petosemtamab shows activity in colorectal cancer
Merus released updated clinical data for petosemtamab showing responses across multiple lines of colorectal cancer, signaling potential use beyond its development focus in head and neck tumors....
Tetraneuron pursues upstream gene‑therapy angle for Alzheimer’s: E2F4 AAV program advances
Tetraneuron presented its E2F4‑focused AAV gene‑therapy approach aimed at upstream drivers of Alzheimer’s disease, arguing that modulating a transcription factor could prevent neurons from...
Deep learning accelerates antibiotic discovery: models mine chemical space for new scaffolds
Researchers reported application of deep‑learning models to rapidly identify novel antibiotic scaffolds and prioritize leads against resistant pathogens. The approach integrates large chemical...
Biogen bets $70M on Vanqua’s C5aR1 antagonist
Biogen has licensed exclusive global rights to Vanqua Bio’s preclinical C5aR1 antagonist, paying $70 million up front and agreeing to as much as $990 million in future milestones. The deal hands...
Lilly buys Adverum — snaps up phase‑3 eye gene therapy
Eli Lilly agreed to acquire cash‑strapped Adverum in a deal that secures ixo‑vec, an AAV‑based gene therapy in phase 3 for wet age‑related macular degeneration. The transaction trades a modest...
Inhibrx posts phase II win — eyes BLA for rare chondrosarcoma
Inhibrx reported that its monoclonal antibody ozekibart met the primary endpoint in a registrational phase II study for advanced or metastatic unresectable chondrosarcoma, producing a...
Gepotidacin wins approval for UTIs; gonorrhea filing pending
Gepotidacin, an oral bacterial type II topoisomerase inhibitor, received regulatory approval in March 2025 for uncomplicated urinary tract infections under the name Blujepa and remains under FDA...
FDA finds unauthorized API warehouse — contamination and compliance flagged
The U.S. Food and Drug Administration disclosed an inspection that uncovered an unauthorized warehouse tied to Indian generic drugmaker Hetero Labs storing drugs and active pharmaceutical...